Bio-Techne (TECH) Set to Announce Quarterly Earnings on Wednesday

Bio-Techne (NASDAQ:TECH) is scheduled to release its earnings data before the market opens on Wednesday, May 1st. Analysts expect Bio-Techne to post earnings of $0.40 per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Bio-Techne (NASDAQ:TECH) last issued its quarterly earnings results on Thursday, February 1st. The biotechnology company reported $0.33 EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.03). The firm had revenue of $272.60 million for the quarter, compared to analysts’ expectations of $277.48 million. Bio-Techne had a return on equity of 14.21% and a net margin of 19.58%. On average, analysts expect Bio-Techne to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bio-Techne Stock Performance

Shares of TECH opened at $64.51 on Tuesday. The company has a market capitalization of $10.14 billion, a price-to-earnings ratio of 46.75, a PEG ratio of 7.97 and a beta of 1.22. The company has a debt-to-equity ratio of 0.23, a quick ratio of 3.03 and a current ratio of 4.37. Bio-Techne has a 1 year low of $51.79 and a 1 year high of $89.91. The company’s 50 day simple moving average is $69.68 and its 200 day simple moving average is $68.44.

Bio-Techne Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 26th. Shareholders of record on Monday, February 12th were issued a $0.08 dividend. This represents a $0.32 annualized dividend and a yield of 0.50%. The ex-dividend date was Friday, February 9th. Bio-Techne’s dividend payout ratio (DPR) is 23.19%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TECH shares. Stifel Nicolaus downgraded shares of Bio-Techne from a “buy” rating to a “hold” rating and set a $65.00 target price for the company. in a report on Friday, February 2nd. Royal Bank of Canada dropped their price target on Bio-Techne from $85.00 to $75.00 and set a “sector perform” rating for the company in a research note on Friday, February 2nd. Deutsche Bank Aktiengesellschaft reduced their price objective on Bio-Techne from $85.00 to $82.00 and set a “buy” rating on the stock in a research note on Thursday, April 18th. Stephens cut their price target on shares of Bio-Techne from $92.00 to $87.00 and set an “overweight” rating on the stock in a report on Friday, February 2nd. Finally, Scotiabank began coverage on shares of Bio-Techne in a research report on Thursday, February 8th. They set a “sector outperform” rating and a $80.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $83.90.

Insider Buying and Selling at Bio-Techne

In related news, Director Roeland Nusse sold 10,400 shares of Bio-Techne stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $76.98, for a total value of $800,592.00. Following the completion of the sale, the director now owns 43,097 shares in the company, valued at $3,317,607.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.10% of the stock is currently owned by corporate insiders.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.